Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism
- PMID: 28335835
- DOI: 10.1016/j.jacc.2016.12.039
Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism
Abstract
Background: The long-term effect of thrombolytic treatment of pulmonary embolism (PE) is unknown.
Objectives: This study investigated the long-term prognosis of patients with intermediate-risk PE and the effect of thrombolytic treatment on the persistence of symptoms or the development of late complications.
Methods: The PEITHO (Pulmonary Embolism Thrombolysis) trial was a randomized (1:1) comparison of thrombolysis with tenecteplase versus placebo in normotensive patients with acute PE, right ventricular (RV) dysfunction on imaging, and a positive cardiac troponin test result. Both treatment arms received standard anticoagulation. Long-term follow-up was included in the third protocol amendment; 28 sites randomizing 709 of the 1,006 patients participated.
Results: Long-term (median 37.8 months) survival was assessed in 353 of 359 (98.3%) patients in the thrombolysis arm and in 343 of 350 (98.0%) in the placebo arm. Overall mortality rates were 20.3% and 18.0%, respectively (p = 0.43). Between day 30 and long-term follow-up, 65 deaths occurred in the thrombolysis arm and 53 occurred in the placebo arm. At follow-up examination of survivors, persistent dyspnea (mostly mild) or functional limitation was reported by 36.0% versus 30.1% of the patients (p = 0.23). Echocardiography (performed in 144 and 146 patients randomized to thrombolysis and placebo, respectively) did not reveal significant differences in residual pulmonary hypertension or RV dysfunction. Chronic thromboembolic pulmonary hypertension (CTEPH) was confirmed in 4 (2.1%) versus 6 (3.2%) cases (p = 0.79).
Conclusions: Approximately 33% of patients report some degree of persistent functional limitation after intermediate-risk PE, but CTEPH is infrequent. Thrombolytic treatment did not affect long-term mortality rates, and it did not appear to reduce residual dyspnea or RV dysfunction in these patients. (Pulmonary Embolism Thrombolysis study [PEITHO]; NCT00639743).
Keywords: chronic thromboembolic pulmonary hypertension; long-term survival; prognosis; pulmonary embolism; thrombolysis.
Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Comment in
-
PEITHO Long-Term Outcomes Study: Data Disrupt Dogma.J Am Coll Cardiol. 2017 Mar 28;69(12):1545-1548. doi: 10.1016/j.jacc.2017.01.027. J Am Coll Cardiol. 2017. PMID: 28335836 No abstract available.
Similar articles
-
Incomplete echocardiographic recovery at 6 months predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial.Clin Res Cardiol. 2019 Jul;108(7):772-778. doi: 10.1007/s00392-018-1405-1. Epub 2018 Dec 18. Clin Res Cardiol. 2019. PMID: 30564950 Free PMC article. Clinical Trial.
-
Single-bolus tenecteplase plus heparin compared with heparin alone for normotensive patients with acute pulmonary embolism who have evidence of right ventricular dysfunction and myocardial injury: rationale and design of the Pulmonary Embolism Thrombolysis (PEITHO) trial.Am Heart J. 2012 Jan;163(1):33-38.e1. doi: 10.1016/j.ahj.2011.10.003. Am Heart J. 2012. PMID: 22172434 Clinical Trial.
-
Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial.J Thromb Haemost. 2014 Apr;12(4):459-68. doi: 10.1111/jth.12521. J Thromb Haemost. 2014. PMID: 24484241 Clinical Trial.
-
Clinical update on thrombolytic use in pulmonary embolism: A focus on intermediate-risk patients.Am J Health Syst Pharm. 2018 Sep 1;75(17):1275-1285. doi: 10.2146/ajhp170357. Epub 2018 Jun 12. Am J Health Syst Pharm. 2018. PMID: 29895520 Review.
-
Thrombolytic therapy for submassive pulmonary embolism.Best Pract Res Clin Haematol. 2012 Sep;25(3):379-89. doi: 10.1016/j.beha.2012.06.005. Epub 2012 Aug 4. Best Pract Res Clin Haematol. 2012. PMID: 22959553 Review.
Cited by
-
Low-dose urokinase thrombolytic therapy for patients with acute intermediate-high-risk pulmonary embolism: A retrospective cohort study.PLoS One. 2021 Mar 26;16(3):e0248603. doi: 10.1371/journal.pone.0248603. eCollection 2021. PLoS One. 2021. PMID: 33770113 Free PMC article.
-
Chronic Thromboembolic Pulmonary Hypertension.Lung. 2022 Jun;200(3):283-299. doi: 10.1007/s00408-022-00539-w. Epub 2022 May 29. Lung. 2022. PMID: 35643802 Review.
-
Diagnosis, Treatment and Follow Up of Acute Pulmonary Embolism: Consensus Practice from the PERT Consortium.Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619853037. doi: 10.1177/1076029619853037. Clin Appl Thromb Hemost. 2019. PMID: 31185730 Free PMC article.
-
Risk Stratification of Acute Pulmonary Embolism and Determining the Effect on Chronic Cardiopulmonary Complications: The REACH Study.TH Open. 2020 Mar 30;4(1):e45-e50. doi: 10.1055/s-0040-1708558. eCollection 2020 Jan. TH Open. 2020. PMID: 32259012 Free PMC article.
-
Rethinking Pulmonary Embolism Management with an Interventional Perspective.J Clin Med. 2025 Apr 29;14(9):3085. doi: 10.3390/jcm14093085. J Clin Med. 2025. PMID: 40364116 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical